Phase III trial results of novel triple combination pill for hypertension published in The Lancet
October 18, 2024 07:00 ET
|
George Medicines
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced blood pressure and improved control rates vs dual...
Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress
October 17, 2024 08:30 ET
|
Biognosys AG
Biognosys announced its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany.
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
October 17, 2024 08:07 ET
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
ProductLife Group (PLG) Acquires Halloran to Further Expand Its Global Reach and Capabilities to Support the Development of New Therapies
October 17, 2024 08:00 ET
|
ProductLife Group (PLG)
ProductLife Group (PLG) today announced the acquisition of Halloran Consulting Group, a life science consulting firm.
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
October 17, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
October 17, 2024 07:00 ET
|
BioStem Technologies, Inc.
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
October 16, 2024 16:15 ET
|
OncoCyte Corporation
Oncocyte Announces Participation in the LD Micro Main Event XVII
Conference in Los Angeles
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
October 16, 2024 07:30 ET
|
Cytokinetics, Incorporated
NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global...
FOXO TECHNOLOGIES INC., PROVIDES UPDATE ON 2024 ACCOMPLISHMENTS AND PLANS FOR REMAINDER OF THE YEAR
October 15, 2024 08:30 ET
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), provides a shareholder letter from Mark White, Interim CEO of FOXO, on what...
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
October 15, 2024 06:00 ET
|
Klotho Neurosciences, Inc.
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences